INVESTOR PRESENTATION JUNE 2020 Forward-Looking Statements Except - - PowerPoint PPT Presentation

INVESTOR PRESENTATION

JUNE 2020

Scientists enabling Healthcare™

Except for historical information, the matters discussed herein may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as

• amended. Such statements include declarations regarding the intent, belief or current

expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside

• f the control of the company including, inter alia, the markets for the Company’s

products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2019. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this presentation.

Forward-Looking Statements

ENZ (NYSE)

Through a connection with the market, provide advanced biotechnology solutions to the global healthcare community as affordable, flexible, quality products and services.

Our Mission

$81M (FY19 Revenue) 445 Global Employees operating in 9 countries 450+ Patents and Patent Applications Global Headquarters in NY with a worldwide distribution network Product manufactured under GMP guidelines Clinical services performed at NYS DOH regulated, CAP, CLIA certified facility

Over 40 years of Improving Healthcare through Innovative Technology

Our History

Across the drug development pipeline – from basic research, drug discovery and process

• ptimization through to diagnostics and therapeutics – Enzo provides solutions.

Markets We Serve

Toxicology Bioprocess Vaccine Development Animal Care Clinical Chemistry Molecular Diagnostics Immunology Microbiology Cancer Epigenetics Immunology

Drug Discovery Drug Development Diagnostics & Delivery

Metabolism Neurology Infectious Disease Immunohistochemistry Oncology Pathology Genetics

World Class Management

Leadership Team

Unique vertical integration enables innovation and disruption within the healthcare market Full spectrum of capabilities across global products market: conceptual innovation, product design, manufacturing, product sales, service delivery Capitalizing

• n industry

tailwinds amid tremendous demand for molecular diagnostics Pioneers in Labeling & Detection – From Genome to Whole Cell – Transforming the market Delivering significant cost reduction to the market while maintaining healthy margins Actively addressing COVID-19 from multiple angles Extensive, innovative intellectual property estate Strategically positioned for substantial growth and value creation

Investment Highlights

An Integrated Diagnostics Company

Our Unique Structure

Develop. Invent. Validate.

Advantages of Vertical Integration

Molecular Diagnostics Market Opportunity

Tremendous Demand for Molecular Diagnostics

$4.6 $4.9 $5.2 $5.6 $6.0 $6.5 $7.1 $3 $4 $4 $5 $5 $6 $6 $7 $7 $8 2012 2013 2014 2015 2016 2017 2018

• Molecular diagnostics (MDx) is only a small segment within the ~$170 billion clinical lab market where Enzo sells its
• verall diagnostics offering
• Thousands of labs in the U.S. can be enabled with MDx technologies but lack capability, and today’s MDx technologies

are expensive

• Closed systems, high-cost reagents dominate the segment
• Require specially trained medical technologists
• Inexpensive open systems lack content due to IP barriers

$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 Infectious… Women's Health CT/NG BV HPV HSV HIV HBV HCV

Annual TAM ($ million)

Global North America

Affordable Solutions for Growing Market Pressure

Product Development & Scale Technology & IP Clinical Validation

Enzo’s affordable products and services, relying on their unique integrated structure, reduces cost of goods layering, thereby combating low reimbursement rates

Open System Solution: Enzo’s Molecular Diagnostics Platform

Enzo is Challenging the Norm to Create Economic Value

ADDRESSING COVID-19 FROM MULTIPLE ANGLES

Enzo is well-equipped to provide the testing, processing and detection/analytics for this large and growing market

Complete, Affordable Solutions for COVID-19

Virus Detection

Proprietary Molecular Diagnostic Kits offer improved scale, throughput, and sensitivity CMS reimbursement of $100 per test

IgG/IgM/IgA Immunity

Serological “antibody” diagnostic testing utilizing ELISA CMS reimbursement

• f $42 per analyte per

test

Inflammation

ELISA test that relies

• n a cytokine storm

panel for monitoring

Therapy

Promising proprietary drug candidate for prevention or treatment Patent issued for SK1-I

SARS-CoV-2 Detection with GENFLEX™ Platform

Virus Detection

Virus Detection

SARS-CoV-2 Immunity Detection

IgG/IgM/IgA Immunity

• Immunoglobulin G (IgG)/ Immunoglobulin M

(IgM)/ Immunoglobulin A (IgA) ELISA (enzyme-linked immunosorbent assay) plates for detecting and quantifying antibodies to identify individuals who were infected, with or without symptoms

• Unlike many competitor assays,

differentiates between immunoglobulin, allowing clinicians to identify the different stages of infection

• Test performed in clinical lab using common

lab workflow

• Demonstrates high specificity and high

sensitivity detection

• Turnaround time 24 hours; accurate and

economical results

• Easily scalable

IgG/IgM/IgA Immunity

Swab Test Complemented by Immunity Test Provides a View

• f Disease Progression

COVID-19 Detection

The presence of IgM and IgG antibodies coupled with RT-PCR results demonstrate the possible clinical scenarios that can be encountered. Combining molecular and serological testing can increase the understanding of COVID-19 diagnosis.

IgG/IgM/IgA Immunity Virus Detection

Cytokine Storm Immunoassay for Inflammation Monitoring

Inflammation

• Commercialization of full inflammation panel including detection of

Interleukin 6 (IL-6) levels to enable administration of immunosuppressant to treat Coronavirus patients demonstrating hyper immune response

• Enzo 96-well ELISA plate test is performed in a clinical lab using

common lab workflow

• Turnaround time is 24 hours and results are accurate and

economical

• Easily scalable

Inflammation

Monitoring and Possible Treatment with SK1-I

Therapy

• Potential Use of Drug Candidate SK1-I for Prevention and/or

Treatment of Cytokine Release Syndrome and Respiratory Failure

• Therapeutic studies based on a promising proprietary drug

candidate (SK1-I) which may have potential in the treatment of COVID-19

• Drug has already demonstrated immunosuppressant response in a

recognized, chemically-induced animal model of Lupus and has previously passed preliminary toxicology studies

• FDA approval of existing proprietary product garnering interest as

potential treatment for COVID-19

• U.S. Patent issued

Therapy

POSITIONED FOR SUCCESS THROUGH FOCUSED ADVANCEMENT OF ESTABLISHED TECHNOLOGIES AND PLATFORMS

Applying our capabilities to provide affordable patient care within key diagnostic segments

Our Assets

Enzo Clinical Labs performs 99% of all testing on site, operating 24/7

Full Service Clinical Lab

Full

Services and Accreditations

Full Service Clinical Lab

• Enzo Clinical Labs performs 99% of all testing on site, operating 24/7
• Enzo technology validated for use in high volume clinical testing by a qualified on-site LDT team
• STAT Lab Capabilities
• Extensive courier route within the Northeast
• Field technical staff for client education
• All technical staff are NYS Clinical Laboratory Licensed Technologists
• Licensure in all 50 states
• In network with national and local insurance companies
• (e.g., United Healthcare, Aetna, Cigna, BCBS, Fidelis)
• EMR integration capabilities

Laboratory Accreditations include:

Global Sales and Service Structure

• Global PhD field team to support customer’s technical needs
• Global customer service team, communicating in multiple languages
• Constant customer interaction and education through on-site visits, as well as social

media

• Thousands of products, developed from dozens of technologies, and spanning

hundreds of applications

• Products and platforms cited in thousands of research publications

Supporting our Brand Globally

Product Manufacturing, MI ENZO Headquarters & Clinical Lab Production NY EU Sales Offices BE, CH, DE, FR, UK

9 Direct Sales Offices & 45 Distributors for a Sales & Technical Support in Local Languages 2 Logistics Centers with same-day Global Shipping Capabilities

EU Logistics, CH 12 Distributors covering APAC

Life Sciences Reagents, Kits, and Services

Providing solutions to researchers, drug and diagnostic developers, and clinicians across the globe

FINANCIAL PROFILE

Financial Snapshot

Enzo BioChem Key Financials (FYE July) FY 2019 1Q 2020 2Q 2020 3Q 2020 Revenue $81.2mm $20.2mm $19.4mm $16.9mm

• Adj. EBITDA

$7.1mm ($7.2mm) ($5.3mm) ($6.1mm) Cash & Cash Equivalents $60mm $57mm $52mm $55mm Shareholders Equity $86mm $78mm $71mm $62mm Shares Outstanding 47.6mm 47.6mm 47.6mm 47.8mm

R&D Investment Yields Results

Fully Integrated Company with Comprehensive, End-to-End Solutions for Molecular Clinical Diagnostics

Conclusion

• Unique vertical integration enables innovation and disruption within the healthcare market
• Full spectrum of capabilities across global products market: conceptual innovation, product

design, manufacturing, product sales, service delivery

• Capitalizing on industry tailwinds amid tremendous demand for molecular diagnostics
• Pioneers in labeling and detection – from genome to whole cell – transforming the market
• Delivering significant cost reduction to the market while maintaining healthy margins
• Actively addressing COVID-19 from multiple angles
• Extensive, innovative intellectual property estate with over 450 patents
• Global presence and strategically positioned for substantial growth and value creation

THANK YOU

www.enzo.com IR@enzo.com